Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745349 | 1.00 | GAA (0.49) | GAAFUCA1MEN1TSHRKMT2A | |
| SCHEMBL19000134 | 0.84 | ACHE (0.51) | GAAFUCA1MEN1TSHRKMT2A | |
| SCHEMBL17061829 | 0.84 | FUCA1 (0.56) | GAAFUCA1MEN1TSHRKMT2A | |
| SCHEMBL8140451 | 0.84 | FUCA1 (0.56) | GAAFUCA1MEN1TSHRKMT2A | |
| SCHEMBL20745825 | 0.83 | SIGMAR1 (0.43) | GAAFUCA1SIGMAR1ACHE | |
| SCHEMBL17426439 | 0.83 | SIGMAR1 (0.43) | GAAFUCA1SIGMAR1ACHE | |
| SCHEMBL34473339 | 0.79 | GAA (0.50) | GAAFUCA1MEN1TSHRKMT2A | |
| SCHEMBL9385749 | 0.79 | GAA (0.50) | GAAFUCA1MEN1TSHRKMT2A | |
| SCHEMBL1088536 | 0.79 | FUCA1 (0.60) | FUCA1SIGMAR1ACHEGBA1 | |
| SCHEMBL10990414 | 0.79 | GAA (0.67) | GAAFUCA1MEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035393-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12240869-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240034742-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | MEDIC LIFE SCIENCES, INC. | 2024-02-01 | — | — | US | disclosed |
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-4229038-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3873462-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3873477-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113226306-A | Methods of treating cancer in a patient identified by a biomarker using a non-covalent inhibitor of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3740207-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10738067-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738067-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200190126-A1 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200190126-A1 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2020-06-18 | — | — | US | disclosed |
| WO-2019143719-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| CN-110036004-A | Inhibitors of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2019-07-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034742-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | CDK7, CCNI, CDK17 | GAA 2827/4885FUCA1 2911/4885MEN1 693/4885 |
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | CDK7, CDK3, CCNK | GAA 2580/4885FUCA1 2012/4885MEN1 1124/4885 |
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | GAA 2811/4885FUCA1 3263/4885MEN1 712/4885 |
| US-10738067-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK1, CDK17 | GAA 1476/4885FUCA1 4095/4885MEN1 2300/4885 |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | GAA 2811/4885FUCA1 3263/4885MEN1 712/4885 |
| US-12240869-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK1, CDK17 | GAA 1476/4885FUCA1 4095/4885MEN1 2300/4885 |
| US-20260035393-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNI | GAA 4557/4885FUCA1 3966/4885MEN1 2642/4885 |
| US-20200190126-A1 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | CDK7, CDK1, CDK17 | GAA 1476/4885FUCA1 4095/4885MEN1 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.